Acute Leukaemias

Clinical trials for patients with acute leukaemia. Acute Leukaemia is a type of cancer that affects the blood and bone marrow.

If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information. 

For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.

Clinical Trials Enquiry Coordinator

Business hours, Mon to Friday between 9am - 2pm
Email Clinical Trials Enquiries
Phone (03) 8559 7456

Open and Recruiting Clinical Trials

A clinical trial to test the safety and efficacy of Venetoclax in combination with chemotherapy for the treatment of acute myeloid leukaemia

Cancer type

Acute Myeloid Leukaemia (AML)

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

All participants enrolled in this trial will be given Venetoclax and low intensity chemotherapy. It is hoped that the findings of this trial will provide information on the best dose of Venetoclax in combination with chemotherapy for the safe and effective treatment of AML in older patients with fewer side effects.

Who can participate

Patients who:

  • Aged 60 or over
  • Have been diagnosed with AML
  • Have not received any chemotherapy yet and for whom high intensity chemotherapy may do more

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test if the treatments FT-2102 and Azacitadine are effective in controlling the diseases Acute Myeloid Leukaemia or Myelodysplastic Syndrome in people who have a specific changes in the genes of the cancer (IDH 1)

Cancer type

Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS)

Status

Open and recruiting

Phase

One / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.

Brief summary

Patients will receive one of the following treatments:

  • FT-2102 alone
  • Azacitadine alone
  • FT-2102 and Azacitadine given together

This will depending on the patient’s previous treatments and the changes in the genes of the cancer.

Who can participate

Patients who:

  • Have Acute Myeloid Leukaemia or Myelodysplastic Syndrome that has not responded to previous treatment
  • Specific changes in the genes of the cancer (IDH 1)

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to see whether the treatment Arsenic Trioxide is as effective in controlling Acute Promyelocytic Leukaemia in the form of capsules or as an infusion

Cancer type

Acute Promyelocytic Leukaemia (APML)

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

APML is currently treated by a regular infusion of Arsenic Trioxide given in a hospital clinic. This clinical trial will test if Arsenic Trioxide capsule taken orally at home is as effective as the infusion. Patients will receive both forms of the treatment until one is found to be best.

Who can participate

Patients who:

  • Have been newly diagnosed with APML
  • Are able to swallow medication by mouth

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test safety and effectiveness of the treatments Blinatumomab, Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia

Cancer type

B-precursor Acute Lymphoblastic Leukaemia (B-ALL)

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

People with new diagnoses of B-ALL are commonly treated with standard chemotherapy. This clinical trial tests if the addition of Blinatumomab at the beginning of treatment will achieve long lasting disease control rather than waiting until the cancer potentially comes back.

Who can participate

Patients who:

  • Aged 40 to 65 years old (inclusive)
  • Have newly diagnosed B-precursor acute lymphoblastic leukaemia without Philadelphia positive disease

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test if giving Cyclophosphamide after transplant can prevent graft versus host disease and if this is better than the current standard treatment

Cancer type

Acute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukaemia (ALL)

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

The clinical trial aims to find out if the treatment Cyclophosphamide is better than the current standard of care treatment at preventing graft versus host disease in patients who have just had a bone marrow transplant.

Who can participate

Patients who:

  • Aged 18-70 with AML or ALL which is in remission or MDS with <20% myeloblasts
  • Have a 6/6 matched sibling bone marrow donor

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to find the best dose of a new treatment AMG427 with the fewest side effects for patients who have Acute Myeloid Leukaemia that has not responded or come back after earlier treatment

Cancer type

Acute Myeloid Leukaemia (AML)

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

A clinical trial to find the best dose of a new treatment AMG427 to reduce leukaemia cells in the body without causing too many unpleasant side effects. The treatment is given as an infusion.

Who can participate

Patients who:

  • Have AML that has not changed after previous chemotherapy or that has come back after earlier treatment.
  • No past medical heart, liver or kidney problems.

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.